Hormonal Migraine in Women: What Estrogen, CGRP, and the 2026 Evidence Truly Show
Why the drop in estrogen shortly before menstruation triggers migraines, what the DMKG recommends for short-term prophylaxis, what magnesium, vitamin B2, and coenzyme Q10 have actually achieved in controlled studies – and why an estrogen patch, according to current evidence, tends to postpone attacks rather than prevent them.
Briefly explained (TL;DR)
Migraine affects women about three times as often as men – and for many sufferers, it follows a clear cyclical pattern. The German Migraine and Headache Society (DMKG) defines "menstrual migraine" as attacks occurring in the window from two days before to two days after the start of menstruation – this affects about 7% of all female migraine patients.
According to current research, the trigger is not a hormone "too much" or "too little," but the drop in estrogen levels itself: A study by Charité (Raffaelli et al., 2023) shows that migraine patients release increased amounts of CGRP at exactly this moment – a natural signaling molecule that dilates blood vessels in the brain and is centrally involved in the attack.
Short-term prophylaxis with naproxen or triptans around menstruation is the standard strategy recommended by the DMKG. While an estrogen patch can attenuate attacks during use, a controlled study found that headache days increased by 40% after discontinuation, leading experts to classify this strategy as not permanently effective.
For magnesium, vitamin B2 (riboflavin), and coenzyme Q10, randomized, placebo-controlled studies with specific response rates exist. They are well-researched supplements to medical migraine therapy – not a replacement for it, especially not in the case of migraine with aura, where the choice of contraceptive method is also a proven safety issue.
Important medical notice
This article is intended for health information purposes and does not replace a neurological or gynecological examination. Migraine diagnosis and therapy – including prescription triptans, hormonal preparations, or CGRP antibodies – should be managed by a doctor.
Immediate medical attention is required for the following warning signs, regardless of the cycle: a sudden, extremely severe "thunderclap headache," headache with fever and stiff neck, new-onset neurological deficits (paralysis, speech impairment, vision loss), clouding of consciousness, or a completely new type of headache after age 50. In these cases: call 112 or visit an emergency room immediately.
Women with migraine with aura should explicitly discuss the choice of their contraceptive method with a doctor (see section below) – dietary supplements do not change this and are not a substitute for this assessment.
Why migraine in women so often follows the cycle
Many women with migraines are familiar with the pattern before they even have a word for it: The most intense, most stubborn attack of the month almost always comes at the same time – shortly before or at the start of menstruation. This is neither a coincidence nor imaginary. According to data from the German Migraine and Headache Society (DMKG), migraine affects women about three times as often as men, and a significant portion of this difference can be attributed to female sex hormones.
The DMKG precisely distinguishes between two patterns: migraine that occurs exclusively perimenstrually ("pure menstrual migraine"), and migraine that occurs independently of the cycle but intensifies perimenstrually ("menstrually associated migraine"). According to the DMKG, about 7% of all female migraine patients are affected by the pure form; a significantly larger proportion reports additional intensification around menstruation.
→ Source: DMKG – Migraine and Hormones
The mechanism: Why the estrogen drop releases CGRP
For a long time, the vague formula "hormonal fluctuations trigger migraines" prevailed. A 2023 study published in Neurology by the Department of Neurology at Charité – Universitätsmedizin Berlin, together with the Berlin Institute of Health, has defined this mechanism more concretely.
Dr. Bianca Raffaelli, who led the research team, explains the central finding as follows: When estrogen levels drop to initiate menstruation, migraine patients release increased levels of CGRP – Calcitonin Gene-Related Peptide, an endogenous signaling molecule that is excessively released during migraines and causes strong dilation of blood vessels in the brain. In the study with 180 participants, CGRP concentration during menstruation was significantly higher in migraine patients than in healthy control subjects.
This is the crucial change in perspective: It is not a specific hormone level "per se" that is the problem, but how the migraine-sensitive nervous system reacts to the drop in estrogen – structurally comparable to the principle discussed in other hormone-dependent neurological phenomena. At the same time, this explains why migraine becomes noticeably less frequent in some women after menopause, when cyclic fluctuations disappear.
→ Source: Charité – Raffaelli et al., Neurology (2023): CGRP and estrogen drop in menstrual migraine
Evidence Filter
Confirmed: Migraine is linked to the cycle in a relevant proportion of sufferers; the drop in estrogen before menstruation is a proven trigger.
Well-researched: CGRP as a central signaling molecule of the migraine mechanism, with a direct link to the perimenstrual estrogen drop.
Not supported: That any single hormone value is "too low" or "too high" or can be meaningfully determined via self-testing.
Short-term prophylaxis: What the DMKG specifically recommends
For the perimenstrual phase, there is no "single" therapy, but a stepwise approach described by the DMKG in its patient information leaflet "Migraine and Hormones":
For mild to moderate attacks, long-acting painkillers are recommended, primarily naproxen in a dosage of 500 to 1,000 mg. For moderate to severe attacks, triptans are considered the first-line treatment for acute therapy – they are prescription-only and should be determined individually with a doctor. Concomitant nausea can be treated with metoclopramide or domperidone. Additionally, as a preventive, so-called short-term or "mini-prophylaxis," an estrogen patch can be used, typically applied two days before the expected period and worn throughout menstruation.
→ Source: DMKG – Migraine and Hormones: Recommendations for perimenstrual short-term prophylaxis
The estrogen patch paradox: What a controlled study truly showed
An estrogen patch sounds like the most obvious solution: if the drop in the hormone triggers the attack, one should simply be able to cushion that drop. A placebo-controlled double-blind study by the London Migraine Clinic led by Dr. Anne MacGregor tested exactly this in 38 women with menstrual migraine – with a result that thwarts simple logic.
Participants wore an estradiol gel with 1.5 mg of active ingredient from six days before to two days after the start of menstruation. During the treatment phase, migraine days decreased by 22%. The problem appeared afterward: After discontinuing the gel, headache diaries documented an increase in attacks of 40% – the previously postponed estrogen drop merely took place with a time delay and triggered the migraine there. Experts therefore rated the strategy overall as not permanently effective: it postpones the attack rather than preventing it. As a consequence, triptans are recommended more for acute therapy than an exclusively hormonal strategy.
→ Source: MigräneLiga – MacGregor et al.: Hormone therapy for menstrual migraine not permanently effective
Magnesium: the largest placebo-controlled study to date
Magnesium is not a new trend for migraine but has been the subject of controlled research since the 1990s. The best-known study comes from Peikert and colleagues: 81 migraine patients between 18 and 65 years old with an average attack frequency of 3.6 per month took either 600 mg (24 mmol) of magnesium daily in the form of trimagnesium dicitrate or a placebo for twelve weeks, following a four-week observation phase without treatment.
In the final four weeks of the study, the attack frequency in the magnesium group decreased by 41.6%, compared to 15.8% in the placebo group. The number of days with migraine also decreased significantly in the magnesium group. The most common side effects documented were diarrhea (18.6%) and stomach irritation (4.7%) – an indication that high-dose magnesium is not free of side effects and that the dosage should be adjusted individually.
→ Source: Peikert et al., Cephalalgia (1996): Prophylaxis of Migraine with Oral Magnesium
Vitamin B2 (riboflavin): High-dose prophylaxis with a clear response rate
High-dose riboflavin is one of the best-supported nutrient approaches in migraine prophylaxis. In the randomized, placebo-controlled study by Schoenen and colleagues, 55 migraine patients received either 400 mg of riboflavin or a placebo daily for three months.
Riboflavin was statistically superior to the placebo in reducing both the attack frequency (p = 0.005) and the number of headache days (p = 0.012). The response rate is particularly telling: 59% of the riboflavin group achieved a reduction in attacks of at least 50%, compared to 15% in the placebo group – a "Number Needed to Treat" of 2.3. Overall, only three minor side effects (diarrhea, increased urination) were documented, none of which were serious. Due to its high efficacy, good tolerability, and low cost, the authors rated riboflavin as a promising option for migraine prophylaxis.
→ Source: Schoenen et al., Neurology (1998): Effectiveness of High-Dose Riboflavin in Migraine Prophylaxis
Coenzyme Q10: the third well-researched nutrient pillar
Coenzyme Q10 plays a central role in mitochondrial energy metabolism, which is also discussed in the context of migraine. In the randomized, placebo-controlled study by Sandor and colleagues, migraine patients took 300 mg of coenzyme Q10 or a placebo daily.
The response rate (at least 50% fewer headache days) was 47.6% in the coenzyme Q10 group and 14.4% in the placebo group – a Number Needed to Treat of 3. Coenzyme Q10 is considered well-tolerated; subsequent review studies tend to confirm the prophylactic benefit for migraine but also point out that the number of controlled studies remains manageable, making further, larger-scale investigations desirable.
→ Sources: Sandor et al., Neurology (2005): Efficacy of Coenzyme Q10 in Migraine Prophylaxis · American Academy of Family Physicians – Study Summary
Perimenopause: When hormonal migraine changes rather than disappears
A widespread misconception is that migraines "automatically" disappear with menopause. A congress presentation at the European Academy of Neurology (EAN) in July 2026 by Dr. Anna Szewczyk (Medical University of Lublin) paints a more nuanced picture.
According to Szewczyk, migraine patients in perimenopause frequently report a higher attack frequency, increased pain intensity, and diminishing efficacy of previous medications. The decisive factor here is not menopause itself, but the hormonal fluctuations of the transition phase leading up to it. After entering postmenopause – when the cyclic hormonal fluctuations cease – migraines stabilize for many sufferers. Szewczyk therefore recommends active screening of women between 45 and 55 years of age for changes in their migraine patterns as well as therapy adjustment in case of deterioration. Regarding hormone replacement therapy, she notes that the evidence is mixed, but transdermal application forms (patches, gel) tend to appear better tolerated than other routes of administration.
→ Source: Gelbe Liste – EAN Congress 2026: Dr. Anna Szewczyk on Menopause and Migraine
The new generation: CGRP antibodies for menstrual migraine
For some years, CGRP antibodies (including erenumab) have been available as specifically developed migraine prophylaxis – consistent, given the central role of CGRP in the perimenstrual mechanism. A 2025 study led by Rut Mas-de-les-Valls, Laura Gómez-Dabó, and Patricia Pozo-Rosich specifically investigated the efficacy of CGRP antibodies and onabotulinumtoxinA in menstrually associated migraine.
In doing so, the authors explicitly identify a previously insufficiently resolved point, the so-called "unmet need of perimenstrual headache days": Even under effective CGRP antibody therapy, perimenstrual headache days remain a particular challenge for some patients, requiring additional strategies specifically tailored to the perimenstrual window. This underscores why short-term prophylaxis around the period remains a separate topic even in the era of modern biologics – and is not merely a question of dietary supplements.
Safety issue contraception: Why migraine with aura plays a special role here
One point is often underestimated in practice: In migraine with aura, the choice of contraceptive method is not just a question of comfort, but a documented safety issue. In its "Medical Eligibility Criteria for Contraceptive Use," the WHO explicitly advises against using combined hormonal contraceptives (the "combined pill," patch, vaginal ring with estrogen and progestogen components) for migraine with aura – regardless of age. The German Society for Gynecology and Obstetrics (DGGG) formulates it similarly clearly in its guideline: combined hormonal contraceptives should not be prescribed for migraine with aura.
The background to this is the already increased risk of an ischemic stroke with migraine with aura, which increases further with the additional intake of combined hormonal contraceptives. Pure progestogen preparations ("mini-pill") are considered a better-tolerated alternative for women without other stroke risk factors. This classification explicitly concerns only migraine with aura – it is one more reason to have one's own migraine type (with or without aura) clarified by a doctor before deciding on a contraceptive method.
→ Source: Apotheke Adhoc – WHO/DGGG: Migraine with aura and combined hormonal contraceptives
Evidence Map: What plays what role in hormonal migraine?
| Approach | Evidence | Specific figure | What does not follow from this |
|---|---|---|---|
| Naproxen (perimenstrual) | DMKG recommendation for short-term prophylaxis | 500–1,000 mg | No permanent solution without medical consultation |
| Triptans | DMKG: 1st choice for moderate/severe attacks | Prescription-only | Not a preventative, only acute therapy |
| Estrogen patches | RCT (MacGregor): effective during use | −22 % / +40 % rebound | No permanent solution according to studies |
| Magnesium | RCT (Peikert, n=81) | −41.6 % vs. −15.8 % | Does not replace acute therapy for severe attacks |
| Vitamin B2 (400 mg) | RCT (Schoenen, n=55) | 59 % vs. 15 % response rate | Effect usually only after several weeks |
| Coenzyme Q10 (300 mg) | RCT (Sandor, n=42) | 47.6 % vs. 14.4 % response rate | Still limited number of studies |
| CGRP antibodies | 2025 study on menstruation-associated migraine | Prescription-only | Does not fully resolve perimenstrual days according to authors |
This matrix is an evidence-oriented classification and not an individual therapy recommendation.
VeyT nutrient support for this article
For this article, we exclusively recommend magnesium and coenzyme Q10 as VeyT products – both with a direct link to the randomized studies on migraine prophylaxis cited above. They are to be understood as general nutrient support, not as a substitute for acute therapy, medically prescribed prophylaxis, or clarification of migraine with aura.
SIUM
VeyT Multi-Magnesium Bio-Complex
Magnesium 4-fold complex with 200 mg per daily serving. Categorized in the context of this article as general nutrient support – the cited study worked with 600 mg of trimagnesium dicitrate under medical supervision; individual dosage should be professionally coordinated.
View VeyT Multi-Magnesium Bio-Complex →200mg
VeyT Coenzyme Q10 200mg
Coenzyme Q10 in softgel form, 200 mg per capsule. The cited Sandor study used 300 mg daily, distributed throughout the day; a gradual dose adjustment should be done individually, especially if blood thinners or other medications are taken simultaneously.
View VeyT Coenzyme Q10 200mg →Dietary supplements should not be considered as a substitute for a balanced diet or medical treatment. In the case of existing illnesses, pregnancy, breastfeeding, or regular medication intake, supplementation should be clarified individually.
Practical Protocol: The VeyT Cycle Migraine Tracker
- Keep a headache diary for at least two to three cycles: Cycle day, intensity, duration, aura yes/no, medication taken.
- Check the pattern: Do the strongest attacks reliably occur two days before to two days after the start of your period?
- Discuss with your doctor whether short-term prophylaxis makes sense – naproxen, a triptan, or an estrogen patch, depending on the individual profile.
- Clarify explicitly whether your migraine occurs with or without aura before deciding on a hormonal contraceptive method.
- Use magnesium, vitamin B2, or coenzyme Q10 specifically and with a realistic time horizon – the cited studies ran over eight to twelve weeks, not just a few days.
- In case of worsening during perimenopause (late 40s/early 50s): actively address that the migraine pattern might have changed hormonally, instead of dismissing it as "normal aging."
- In case of warning signs (see medical notice above): seek immediate medical help, regardless of the cycle.
What is not (yet) sufficiently proven
"Hormonal contraception cures migraine"
Continuous hormonal contraception can alleviate perimenstrual fluctuations in some women. However, it is not a universally valid "cure," does not work the same for all women, and is explicitly not recommended for combined preparations for safety reasons in the case of migraine with aura (see above).
"A single hormone test shows the cause"
A spot hormone level does not reflect the dynamic, daily change of estrogen in the cycle. In practice, the symptom pattern documented over several cycles is usually more informative than a single laboratory value.
"Dietary supplements replace medical prophylaxis"
Magnesium, vitamin B2, and coenzyme Q10 are well-studied supplements with real measured response rates – but they do not replace medically prescribed acute or long-term therapy, especially not in the case of frequent, severe, or changing attacks.
Editorial Verdict: Understanding the cycle instead of treating symptoms in isolation
Hormonal migraine is not a diffuse wellness topic, but a clearly described clinical pattern with a mechanism that is now well understood: the CGRP increase as a reaction to the perimenstrual estrogen drop. Anyone who knows the pattern can respond more specifically instead of being surprised by the same attack again every month.
The DMKG recommendations for short-term prophylaxis – naproxen, triptans, possibly an estrogen patch under medical supervision – form the medically sound basis. Magnesium, vitamin B2, and coenzyme Q10 are well-tolerated supplements proven by randomized studies and specific response rates, but they are not an alternative to medical clarification. And especially with migraine with aura, the contraceptive question is not a triviality, but a documented safety decision.
The latest research – from the Charité CGRP study to the EAN-2026 data on perimenopause to the 2025 study on CGRP antibodies – also shows: even with the most modern therapies available, the perimenstrual time window remains a separate challenge for many women. That is precisely why a systematic, cycle-related approach is worthwhile – from documentation to the conversation with a migraine-experienced practice.
Frequently asked questions about hormonal migraine
What is the difference between menstrual and menstruation-associated migraine?
Pure menstrual migraine occurs exclusively in the time window of two days before to two days after the start of the period and, according to the DMKG, affects about 7% of migraine patients. Menstruation-associated migraine also occurs outside this window but intensifies perimenstrually.
Why does the estrogen drop trigger migraine?
A Charité study (Raffaelli et al., 2023) shows that migraine patients increasingly release CGRP when estrogen levels drop – a messenger substance that dilates blood vessels in the brain and is centrally involved in the migraine mechanism.
Do estrogen patches help with menstrual migraine?
It can reduce attacks during use, but according to a controlled study, it merely shifts them – after discontinuation, migraine days increased by 40%. Experts therefore do not recommend it as a sole permanent solution.
Which nutrients are best studied for migraine?
Magnesium, vitamin B2 (riboflavin, 400 mg), and coenzyme Q10 (300 mg) have randomized, placebo-controlled studies with documented response rates between approximately 42% and 59%.
Does migraine disappear automatically during menopause?
Not necessarily. In perimenopause, many women initially report a worsening; according to EAN-2026 congress data, the migraine stabilizes for many affected individuals only after entering postmenopause.
Am I allowed to take the birth control pill with migraine?
For migraine with aura, the WHO and DGGG explicitly advise against combined hormonal contraceptives, as the stroke risk increases additionally. Pure progestogen preparations are considered a better-tolerated alternative. This decision belongs in medical hands.
What is not sufficiently helped by CGRP antibodies?
A study published in 2025 describes that perimenstrual headache days remain a particular challenge for some patients even under CGRP antibody therapy – an "unmet need" that requires targeted additional strategies.
When should I see a doctor immediately for headaches?
In the case of a sudden "thunderclap" headache, fever with neck stiffness, new neurological deficits, clouding of consciousness, or a completely new type of headache after the age of 50 – regardless of the cycle. In these cases, call 112 immediately or go to an emergency room.
References & Scientific Citations
- DMKG – Migraine and Hormones (Patient Information)
- Charité – Raffaelli et al., Neurology (2023)
- MigräneLiga – MacGregor et al.: Hormone therapy for menstrual migraine
- Peikert et al., Cephalalgia (1996) – Magnesium in migraine prophylaxis
- Schoenen et al., Neurology (1998) – Riboflavin in migraine prophylaxis
- Sandor et al., Neurology (2005) – Coenzyme Q10 in migraine prophylaxis
- American Academy of Family Physicians – Coenzyme Q10 study summary
- Gelbe Liste – EAN Congress 2026: Szewczyk on menopause and migraine
- Mas-de-les-Valls, Gómez-Dabó, Pozo-Rosich et al. (2025) – CGRP antibodies in menstrual migraine
- Apotheke Adhoc – WHO/DGGG on migraine with aura and contraception
- VeyT – Multi-Magnesium Bio-Complex
- VeyT – Coenzyme Q10 200mg
Transparency of sources: Clinical statements regarding the diagnosis and treatment of hormonal migraine are primarily categorized based on professional society guidelines (DMKG, WHO, DGGG), randomized controlled trials, and current conference reporting. Mechanistic research, individual studies, and expert opinions are not equated with therapy recommendations applicable to every individual.
